diazoxide
Orphan DrugFDA Approved, EMA Approved
Description
Diazoxide is a potassium channel activator that inhibits insulin secretion from pancreatic beta cells. It is the primary medical therapy for congenital hyperinsulinism, including forms caused by SUR1 deficiency. The drug helps prevent severe hypoglycemia in affected patients.
Indications & Therapeutic Use
congenital hyperinsulinism, hyperinsulinemic hypoglycemia, autosomal dominant hyperinsulinism
Global Availability (6 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
diazoxide
| Generic Name | diazoxide |
| Brands | 1 brand available |
| Active Ingredient | diazoxide |
| Drug Class | congenital hyperinsulinism |
| Manufacturer | Teva Pharmaceuticals |
| Dosage Forms | Oral suspension, 50mg/mL |
| Medical Code | C01BD01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00000611 |
| Countries | 6 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations7 Validated Nodes